Will the Supect’s insurance benefit end the cruelty of domestic anticancer drugs?
A chronic myeloid leukemia(CML) treatment, ‘Supect(generic name: radotinib)’ has drawn attention if it would end the cruelty of domestic anticancer drugs as approved as a primary treatment with the health insurance benefit. The cruelty has been continued by the first domestic anticancer drug, Sun...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
